Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Insulin Icodec vs Glargine in Type 1 Diabetes
NCT03723772Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state at Day 50. Started Nov 2018; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03723772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03723772.